HARBIN, China, April 7, 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (NASDAQ: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced that the Company, jointly with Heilongjiang Traditional Chinese Medical University ("HTCMU"), has obtained production licenses for thirteen new medical products from the Heilongjiang Food and Drug Administration ("Heilongjiang FDA") in China. These thirteen products include:No.
Kang Xi Eye Patch2
KangXi Dental Ulcer Membrane3
KangXi Anti-virus Mouthwash4
KangXi Dental Ulcer Mouthwash5
KangXi Snore Stopper6
Kang Xi Periarthritis Shoulder Patch7
KangXi Cervical Vertebrae Patch8
KangXi Lumbar Patch9
KangXi Rheumatoid Patch10
KangXi Hyperostosis Patch11
BiChang Nose Patch12
YuFu Scar Patch13
YuFu Wound Healing PatchChina Sky One is preparing for trial production and searching for the best production process for these thirteen products, which the Company expects to introduce to the market as soon as the fourth quarter of 2011.
"We are pleased to obtain production licenses for these exciting new products, which as a group we believe will contribute materially to China Sky One's revenue and net income in 2012," commented Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "As these mostly external-use medical products dovetail well with our existing production facilities and sales network, we expect to manufacture and sell them efficiently without much extra effort. Going forward, we plan to strengthen our partnership with research institutions such as HTCMU, leveraging their R&D capabilities to enrich our product portfolio and improve the Company's profitability."
About China Sky One Medical, Inc.